Simultaneous determination of antidementia drugs in human plasma: Procedure transfer from HPLC-MS to UPLC-MS/MS.

Détails

Ressource 1Demande d'une copieTélécharger: BIB_729D59AF62E3.P001.pdf (921.45 [Ko])
Etat: Supprimée
Version: de l'auteur⸱e
ID Serval
serval:BIB_729D59AF62E3
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Simultaneous determination of antidementia drugs in human plasma: Procedure transfer from HPLC-MS to UPLC-MS/MS.
Périodique
Journal of Pharmaceutical and Biomedical Analysis
Auteur⸱e⸱s
Noetzli M., Ansermot N., Dobrinas M., Eap C.B.
ISSN
1873-264X (Electronic)
ISSN-L
0731-7085
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
64-65
Pages
16-25
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
A previously developed high performance liquid chromatography mass spectrometry (HPLC-MS) procedure for the simultaneous determination of antidementia drugs, including donepezil, galantamine, memantine, rivastigmine and its metabolite NAP 226-90, was transferred to an ultra performance liquid chromatography system coupled to a tandem mass spectrometer (UPLC-MS/MS). The drugs and their internal standards ([(2)H(7)]-donepezil, [(13)C,(2)H(3)]-galantamine, [(13)C(2),(2)H(6)]-memantine, [(2)H(6)]-rivastigmine) were extracted from 250μL human plasma by protein precipitation with acetonitrile. Chromatographic separation was achieved on a reverse phase column (BEH C18 2.1mm×50mm; 1.7μm) with a gradient elution of an ammonium acetate buffer at pH 9.3 and acetonitrile at a flow rate of 0.4mL/min and an overall run time of 4.5min. The analytes were detected on a tandem quadrupole mass spectrometer operated in positive electrospray ionization mode, and quantification was performed using multiple reaction monitoring. The method was validated according to the recommendations of international guidelines over a calibration range of 1-300ng/mL for donepezil, galantamine and memantine, and 0.2-50ng/mL for rivastimgine and NAP 226-90. The trueness (86-108%), repeatability (0.8-8.3%), intermediate precision (2.3-10.9%) and selectivity of the method were found to be satisfactory. Matrix effects variability was inferior to 15% for the analytes and inferior to 5% after correction by internal standards. A method comparison was performed with patients' samples showing similar results between the HPLC-MS and UPLC-MS/MS procedures. Thus, this validated UPLC-MS/MS method allows to reduce the required amount of plasma, to use a simplified sample preparation, and to obtain a higher sensitivity and specificity with a much shortened run-time.
Pubmed
Web of science
Création de la notice
05/04/2012 16:18
Dernière modification de la notice
20/08/2019 15:30
Données d'usage